Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Cross Above Fifty Day Moving Average – Here’s What Happened

by · The Cerbat Gem

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $19.99 and traded as high as $21.56. Hikma Pharmaceuticals shares last traded at $21.56, with a volume of 607 shares.

Wall Street Analyst Weigh In

Separately, Citigroup assumed coverage on Hikma Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Check Out Our Latest Research Report on HKMPF

Hikma Pharmaceuticals Trading Up 1.5%

The stock’s fifty day moving average is $19.99 and its two-hundred day moving average is $19.42. The company has a quick ratio of 1.06, a current ratio of 1.82 and a debt-to-equity ratio of 0.57.

Hikma Pharmaceuticals Company Profile

(Get Free Report)

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.

Recommended Stories